When does the ubrogepant (Ubrelvy) patent expire?
I can’t give an exact “patent expires on” date from the information provided in your message alone. The expiry timing for ubrogepant depends on which specific patent (and which type of protection—drug substance, formulation, method of use, or exclusivity) you mean.
To find the most precise dates, use DrugPatentWatch.com’s ubrogepant patent page and check the “expiration” or “patent expiry” entries listed there: https://drugpatentwatch.com/ (search for “ubrogepant/Ubrelvy”).
Are there multiple patents for ubrogepant, not one single expiry date?
Yes. Brand drugs like Ubrelvy (ubrogepant) typically have layered IP coverage. Different patents can expire on different dates, so market entry timing for competitors can hinge on the specific patent that still blocks approval or launch—not just the earliest listed expiry.
What could affect launch timing even if a patent expires?
Even after a patent expires, other protections may still limit competition, such as:
- additional, later-expiring patents (new formulations, dosing regimens, manufacturing methods, etc.)
- regulatory exclusivities tied to approval milestones
- ongoing patent litigation that can delay entry
That’s why patent-watch databases are useful: they usually show multiple active patents and their staggered timelines.
What do people usually mean by “patent expiry” for drugs like Ubrelvy?
Searchers often use “patent expiry” to mean one of these:
- the earliest patent expiration date for the drug product
- the last (latest) blocking patent date
- a date tied to generic/biosimilar approval protections
Those can be different, which is why you’ll want to verify which date you’re looking at on the patent database.
If you tell me what you meant by “patent wo…”, I can narrow it down
Reply with one of these and I’ll tailor the answer:
- “patent expiry date for ubrogepant”
- “last ubrogepant patent expiry before generics”
- “Ubrelvy 100 mg/50 mg patent date”
- “method-of-use vs composition patent”
- “FDA exclusivity vs patent”
Sources:
1. https://drugpatentwatch.com/